
A sensory-motor-sensory circuit underlies antinociception ignited by primary motor cortex in mice
Brief intro:
- Author: Fei Wang, Zhi-Cheng Tian, Hui Ding, Xin-Jiang Yang, Fu-Dong Wang, Ruo-Xin Ji, Lei Xu, Zi-Xuan Cao, Sui-Bin Ma, Ming Zhang, Ya-Ting Cui, Xiang-Yu Cong, Wen-Guang Chu, Zhen-Zhen Li, Wen-Juan Han, Yong-Heng Gao, Yuan-Wang Yu, Xiang-Hui Zhao, Wen-Ting Wang, Rou-Gang Xie, Sheng-Xi Wu, Ceng Luo
- Journal: Neuron
- Doi: https://www.doi.org/10.1016/j.neuron.2025.03.027
- Publication Date: 2025 Apr 15
Abstract
Sensory-motor integration is crucial in the processing of chronic pain. The primary motor cortex (M1) is emerging as a promising target for chronic pain treatment. However, it remains elusive how nociceptive sensory inputs influence M1 activity and how rectifying M1 defects, in turn, regulates pain processing at cellular and network levels. We show that injury/inflammation leads to hypoactivity of M1Glu pyramidal neurons by excitation-inhibition imbalance between the primary somatosensory cortex (S1) and the M1. The impaired M1 output further weakens inputs to excitatory parvalbumin neurons of the lateral hypothalamus (LHPV) and impairs the descending inhibitory system, hence exacerbating spinal nociceptive sensitivity. When rectifying M1 defects with repetitive transcranial magnetic stimulation (rTMS), the imbalance of the S1-M1 microcircuitry can be effectively reversed, which aids in restoring the ability of the M1 to trigger the descending inhibitory system, thereby alleviating nociceptive hypersensitivity. Thus, a sensory-motor-sensory loop is identified for pain-related interactions between the sensory and motor systems and can be potentially exploited for treating chronic pain.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
